Insider Trading Alert - PCLN, PPBI And OFIX Traded By Insiders

Stocks with insider trader activity include PCLN, PPBI and OFIX
By TheStreet Wire ,

Friday, Nov. 6, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.82 to $10,527,076.00.

Highlighted Stocks Traded by Insiders:

Priceline Group (PCLN) - FREE Research Report

Tans Gillian, who is President & COO, Booking.com at Priceline Group, sold 161 shares at $1,465.95 on Nov. 6, 2015. Following this transaction, the President & COO, Booking.com owned 1,449 shares meaning that the stake was reduced by 10% with the 161-share transaction.

The shares most recently traded at $1,371.07, down $94.88, or 6.92% since the insider transaction. Historical insider transactions for Priceline Group go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 11,322
  • 24-Week # shares sold: 17,322

The average volume for Priceline Group has been 617,600 shares per day over the past 30 days. Priceline Group has a market cap of $74.2 billion and is part of the services sector and diversified services industry. Shares are up 27.16% year-to-date as of the close of trading on Friday.

The Priceline Group Inc. provides online travel and travel related reservation and search services. The company has a P/E ratio of 32.6. Currently, there are 13 analysts who rate Priceline Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCLN - FREE

TheStreet Quant Ratings

rates Priceline Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Priceline Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pacific Premier Bancorp (PPBI) - FREE Research Report

Garrett Joseph L, who is Director at Pacific Premier Bancorp, bought 3,050 shares at $22.16 on Nov. 6, 2015. Following this transaction, the Director owned 58,800 shares meaning that the stake was boosted by 5.47% with the 3,050-share transaction.

The shares most recently traded at $23.63, up $1.47, or 6.23% since the insider transaction. Historical insider transactions for Pacific Premier Bancorp go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 5,800
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 12,250
  • 24-Week # shares sold: 10,000

The average volume for Pacific Premier Bancorp has been 99,000 shares per day over the past 30 days. Pacific Premier Bancorp has a market cap of $482.7 million and is part of the financial sector and banking industry. Shares are up 37.33% year-to-date as of the close of trading on Friday.

Pacific Premier Bancorp, Inc. operates as the bank holding company for Pacific Premier Bank that provides banking services to professionals, real estate investors, and non-profit organizations in Southern California. The company has a P/E ratio of 21.4. Currently, there are 5 analysts who rate Pacific Premier Bancorp a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PPBI - FREE

TheStreet Quant Ratings

rates Pacific Premier Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, solid stock price performance and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Pacific Premier Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Orthofix International (OFIX) - FREE Research Report

Schumm Jeffrey, who is Chief Administrative Officer at Orthofix International, sold 15,000 shares at $40.67 on Nov. 6, 2015. Following this transaction, the Chief Administrative Officer owned 68,882 shares meaning that the stake was reduced by 17.88% with the 15,000-share transaction.

Mason Brad, who is Ceo at Orthofix International, sold 15,018 shares at $40.60 on Nov. 6, 2015. Following this transaction, the Ceo owned 140,256 shares meaning that the stake was reduced by 9.67% with the 15,018-share transaction.

The shares most recently traded at $40.62, up $0.02, or 0.04% since the insider transaction. Historical insider transactions for Orthofix International go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 5,709
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 5,709
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 5,709

The average volume for Orthofix International has been 96,300 shares per day over the past 30 days. Orthofix International has a market cap of $764.1 million and is part of the health care sector and health services industry. Shares are up 37.59% year-to-date as of the close of trading on Friday.

Orthofix International N.V., a medical device company, provides reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. Currently, there are 2 analysts who rate Orthofix International a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OFIX - FREE

TheStreet Quant Ratings

rates Orthofix International as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full

Orthofix International Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...